GlucoTrack IncNASDAQ:GCTKNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE2.0900
- TODAY'S CHANGE (%)-0.2000 (-8.7336%)
- Bid / Lots2.0200/ 50
- Ask / Lots2.8900/ 3
- Open / Previous Close2.3014 / 2.2900
- Day Range
- 52 Week Range
- Volume5,807
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | GCTK |
|---|---|---|
| 09:36 ET | 400 | 2.29 |
| 09:43 ET | 147 | 2.29 |
| 10:46 ET | 795 | 2.26 |
| 11:22 ET | 100 | 2.225 |
| 01:21 ET | 800 | 2.2145 |
| 01:37 ET | 240 | 2.18 |
| 01:50 ET | 400 | 2.12 |
| 01:55 ET | 200 | 2.11 |
| 01:57 ET | 200 | 2.1 |
| 02:00 ET | 500 | 2.1 |
| 02:40 ET | 100 | 2.1 |
| 03:18 ET | 100 | 2.0831 |
| 03:20 ET | 100 | 2.1 |
| 03:56 ET | 200 | 2.09 |
Jun 20, 2024
*DJ GlucoTrack Appoints Andy Balo to Its Board of Directors >GCTK, from 8:32AM ET on Thursday Jun 20, 2024 by Dow Jones
8:32AM ET on Thursday Jun 20, 2024 by Dow JonesGLUCOTRACK ANNOUNCES THE APPOINTMENT OF ANDY BALO TO BOARD OF DIRECTORS, from 8:30AM ET on Thursday Jun 20, 2024 by Dow Jones
8:30AM ET on Thursday Jun 20, 2024 by Dow JonesGLUCOTRACK ANNOUNCES THE APPOINTMENT OF ANDY BALO TO BOARD OF DIRECTORS, from 8:30AM ET on Thursday Jun 20, 2024 by Dow Jones
8:30AM ET on Thursday Jun 20, 2024 by Dow Jones
Jun 13, 2024
GLUCOTRACK REPORTS SUCCESSFUL COMPLETION OF FIRST REPORTED LONG-TERM PRECLINICAL STUDY OF ITS EPIDURAL GLUCOSE MONITORING SENSOR, from 9:19AM ET on Thursday Jun 13, 2024 by Dow Jones
9:19AM ET on Thursday Jun 13, 2024 by Dow JonesGLUCOTRACK REPORTS SUCCESSFUL COMPLETION OF FIRST REPORTED LONG-TERM PRECLINICAL STUDY OF ITS EPIDURAL GLUCOSE MONITORING SENSOR, from 9:19AM ET on Thursday Jun 13, 2024 by Dow Jones
9:19AM ET on Thursday Jun 13, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
GlucoTrack Inc | 12.5M | -1.1x | --- |
X T L Biopharmaceuticals Ltd | 12.6M | -7.0x | --- |
Enzon Pharmaceuticals Inc | 12.6M | 50.7x | -60.21% |
Cell MedX Corp | 12.8M | -11.7x | --- |
Check Cap Ltd | 12.3M | -0.7x | --- |
Kiora Pharmaceuticals Inc | 12.1M | -0.3x | --- |
Company Information
GlucoTrack, Inc. is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is developing an implantable continuous glucose monitoring (CGM) for use by Type 1 diabetes patients as well as insulin-dependent Type 2 patients. It is developing an implantable continuous blood glucose monitor (CBGM). This product is designed to have an approximately two-year implant longevity without the requirement for any wearable components. The CBGM utilizes an intravascular approach, in which the device is implanted subcutaneously and connected to a lead that is placed directly into a blood vessel. This facilitates continuous blood glucose measurements with zero lag time. The Company is also developing the Glucotrack CBGM a companion mobile application and a cloud-based solution to provide real time, data-driven personalized tools to effectively help a user manage their diabetes and assist healthcare providers with making treatment decisions.
Contact Information
- Headquarters
- 301 Rte 17 North, Ste. 800RUTHERFORD, NJ, United States 07070
- Phone
- 201-842-7715
- Fax
- 302-655-5049
Executives
- Chief Executive Officer
- Paul Goode
- Chief Financial Officer
- James Cardwell
- Vice President - Engineering
- James Thrower
- Director
- Erin Carter
- Director
- Andrew Sycoff
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $12.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 5.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.08 |
EPS | $-1.87 |
Book Value | $0.77 |
P/E Ratio | -1.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
